Short-term IL-1β blockade reduces monocyte CD11b integrin expression in an IL-8 dependent fashion in patients with type 1 diabetes
| Autor: | Nathan Standifer, Carla J. Greenbaum, Gerald T. Nepom, Jenna Bollyky, Srinath Sanda, Jessica A. Hamerman |
|---|---|
| Rok vydání: | 2010 |
| Předmět: |
Adult
Adolescent medicine.medical_treatment Interleukin-1beta Immunology Inflammation Monocytes Young Adult Humans Hypoglycemic Agents Immunology and Allergy Medicine Interleukin 8 Anakinra CD11b Antigen biology business.industry Monocyte Interleukin-8 Interleukin Middle Aged Blockade Interleukin 1 Receptor Antagonist Protein Diabetes Mellitus Type 1 Cytokine medicine.anatomical_structure Integrin alpha M biology.protein medicine.symptom business medicine.drug |
| Zdroj: | Clinical Immunology. 136:170-173 |
| ISSN: | 1521-6616 |
| Popis: | Objective Interleukin 1-beta (IL-1β) is a major inflammatory cytokine. Blockade of the IL-1β pathway is therapeutically efficacious in type 2 diabetes, but the mechanistic effects on the immune system are incompletely understood. Research design We administered an IL-1 receptor antagonist, anakinra, to 7 type 1 diabetes patients in order to investigate the immunologic and metabolic effects of this drug. Mechanistic assays were performed before and after drug administration. Results A novel signature was observed, with reduced serum interleukin 8 (IL-8) levels and reduced CD11b integrin expression on monocytes associated with increased CXCR1 expression. Conclusions This set of linked phenotypes suggests that blockade of the IL-1β pathway results in the reduced ability of mononuclear cells to traffic to sites of inflammation. Mechanistic studies from large scale trials using IL-1 blockade in type 1 diabetes should focus on changes in monocyte trafficking and the IL-8 pathway. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect